From Metastatic Disease Treatment to Adjuvant Strategy: Clinical Translation of a Personalised Neoantigen Immunotherapy Program in Hepatocellular Carcinoma
- Clinical learnings from GT-30, including the favourable safety profile observed with a personalised neoantigen immunotherapy regimen even in advanced hepatocellular carcinoma patients treated in combination with pembrolizumab
- The scientific and development rationale for moving into GT-31, an adjuvant monotherapy study in hepatocellular carcinoma patients with no active radiographic disease, where lower tumour burden and immune priming may provide a stronger setting for benefit
- Key design considerations for personalised neoantigen trials in hepatocellular carcinoma, including novel endpoint strategy, surveillance and recurrence assessment, feasibility of individualised manufacturing, and how to generate a package that is both clinically meaningful and developmentally scalable